GB201908012D0 - TGF-Beta vaccine - Google Patents

TGF-Beta vaccine

Info

Publication number
GB201908012D0
GB201908012D0 GBGB1908012.6A GB201908012A GB201908012D0 GB 201908012 D0 GB201908012 D0 GB 201908012D0 GB 201908012 A GB201908012 A GB 201908012A GB 201908012 D0 GB201908012 D0 GB 201908012D0
Authority
GB
United Kingdom
Prior art keywords
tgf
beta vaccine
vaccine
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1908012.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IO Biotech ApS
Original Assignee
IO Biotech ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IO Biotech ApS filed Critical IO Biotech ApS
Priority to GBGB1908012.6A priority Critical patent/GB201908012D0/en
Publication of GB201908012D0 publication Critical patent/GB201908012D0/en
Priority to CN202080040978.4A priority patent/CN113966342B/zh
Priority to CA3141744A priority patent/CA3141744A1/en
Priority to EP20731430.3A priority patent/EP3980449A1/en
Priority to AU2020287902A priority patent/AU2020287902B9/en
Priority to US17/616,382 priority patent/US20220315634A1/en
Priority to MX2021014856A priority patent/MX2021014856A/es
Priority to JP2021571915A priority patent/JP7758573B2/ja
Priority to PCT/EP2020/065472 priority patent/WO2020245264A1/en
Priority to KR1020227000403A priority patent/KR20220018566A/ko
Priority to SG11202112416XA priority patent/SG11202112416XA/en
Priority to IL288673A priority patent/IL288673A/en
Priority to JP2025170954A priority patent/JP2026010046A/ja
Priority to AU2026200314A priority patent/AU2026200314A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001134—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/4229—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/844—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GBGB1908012.6A 2019-06-05 2019-06-05 TGF-Beta vaccine Ceased GB201908012D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GBGB1908012.6A GB201908012D0 (en) 2019-06-05 2019-06-05 TGF-Beta vaccine
SG11202112416XA SG11202112416XA (en) 2019-06-05 2020-06-04 Tgf-beta vaccine
MX2021014856A MX2021014856A (es) 2019-06-05 2020-06-04 Vacuna de tgf-beta.
PCT/EP2020/065472 WO2020245264A1 (en) 2019-06-05 2020-06-04 Tgf-beta vaccine
EP20731430.3A EP3980449A1 (en) 2019-06-05 2020-06-04 Tgf-beta vaccine
AU2020287902A AU2020287902B9 (en) 2019-06-05 2020-06-04 TGF-beta vaccine
US17/616,382 US20220315634A1 (en) 2019-06-05 2020-06-04 Tgf-beta vaccine
CN202080040978.4A CN113966342B (zh) 2019-06-05 2020-06-04 TGF-β疫苗
JP2021571915A JP7758573B2 (ja) 2019-06-05 2020-06-04 Ｔｇｆ－ベータワクチン
CA3141744A CA3141744A1 (en) 2019-06-05 2020-06-04 Tgf-beta vaccine
KR1020227000403A KR20220018566A (ko) 2019-06-05 2020-06-04 Tgf-베타 백신
IL288673A IL288673A (en) 2019-06-05 2021-12-05 tgf beta vaccine
JP2025170954A JP2026010046A (ja) 2019-06-05 2025-10-09 Ｔｇｆ－ベータワクチン
AU2026200314A AU2026200314A1 (en) 2019-06-05 2026-01-16 TGF-beta vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1908012.6A GB201908012D0 (en) 2019-06-05 2019-06-05 TGF-Beta vaccine

Publications (1)

Publication Number Publication Date
GB201908012D0 true GB201908012D0 (en) 2019-07-17

Family

ID=67385796

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1908012.6A Ceased GB201908012D0 (en) 2019-06-05 2019-06-05 TGF-Beta vaccine

Country Status (12)

Country Link
US (1) US20220315634A1 (enExample)
EP (1) EP3980449A1 (enExample)
JP (2) JP7758573B2 (enExample)
KR (1) KR20220018566A (enExample)
CN (1) CN113966342B (enExample)
AU (2) AU2020287902B9 (enExample)
CA (1) CA3141744A1 (enExample)
GB (1) GB201908012D0 (enExample)
IL (1) IL288673A (enExample)
MX (1) MX2021014856A (enExample)
SG (1) SG11202112416XA (enExample)
WO (1) WO2020245264A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4269429A4 (en) * 2020-12-23 2025-07-30 Korea Inst Sci & Tech NEW PEPTIDE CAPABLE OF INHIBITING TGF-BETA SIGNALING AND ITS UTILIZATION
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy
JPWO2023224096A1 (enExample) * 2022-05-18 2023-11-23
GB202215997D0 (en) 2022-10-28 2022-12-14 Io Biotech Aps Therapy
GB202216449D0 (en) 2022-11-04 2022-12-21 Io Biotech Aps TGF-BETA1 vaccine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
EP0877031A1 (en) * 1997-05-06 1998-11-11 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) TGF-Beta1 derived peptides mimicking the activity of transforming growth factor-Beta1
CA2259956A1 (en) 1997-05-12 1998-11-19 Kyowa Hakko Kogyo Co., Ltd. Peptides promoting the activation of latent tgf-.beta. and method for screening tgf-.beta. activity regulators
US6500920B1 (en) * 1997-06-19 2002-12-31 St. Louis University Inhibitor of transforming growth factor β and A method of inhibiting the biological effects of transforming growth factor
AU2001246393A1 (en) * 2000-03-31 2001-10-08 Vaccine Chip Technology Aps Immunostimulating properties of a fragment of tgf-beta
US8158589B2 (en) * 2003-08-22 2012-04-17 Proyecto Biomedicine Cima, S.L. Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
JPWO2005105144A1 (ja) * 2004-04-30 2007-09-13 協和醗酵工業株式会社 潜在型ＴＧＦ−βの活性化抑制剤
EP1974740A4 (en) * 2005-10-24 2010-09-01 Proyecto Biomedicina Cima Sl USE OF TGF-BETA1 INHIBITORY PEPTIDES IN THE PREPARATION OF AN IMMUNE RESPONSE MODULATING AGENT
WO2009117597A1 (en) 2008-03-21 2009-09-24 The Brigham And Women's Hospital, Inc. Modulation of the immune response
US8476246B2 (en) 2009-07-30 2013-07-02 Antisense Pharma Gmbh Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta system
CN103087173B (zh) * 2013-01-16 2014-07-16 西安交通大学医学院第一附属医院 基于TGF-β1的B细胞抗原表位的合成肽疫苗及其应用
RS61778B1 (sr) * 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
AU2015229381B2 (en) * 2014-03-11 2019-11-07 University Of Florida Research Foundation, Inc. Use of AAV-expressed M013 protein as an anti-inflammatory therapeutic

Also Published As

Publication number Publication date
AU2020287902B2 (en) 2025-10-16
KR20220018566A (ko) 2022-02-15
AU2020287902B9 (en) 2025-10-30
CN113966342A (zh) 2022-01-21
JP2022535102A (ja) 2022-08-04
CN113966342B (zh) 2026-03-24
WO2020245264A1 (en) 2020-12-10
SG11202112416XA (en) 2021-12-30
JP7758573B2 (ja) 2025-10-22
MX2021014856A (es) 2022-02-11
IL288673A (en) 2022-02-01
AU2020287902A1 (en) 2021-12-02
EP3980449A1 (en) 2022-04-13
US20220315634A1 (en) 2022-10-06
CA3141744A1 (en) 2020-12-10
JP2026010046A (ja) 2026-01-21
AU2026200314A1 (en) 2026-02-05

Similar Documents

Publication Publication Date Title
GB202010425D0 (en) Combination vaccine
SG11202010821TA (en) Vaccine composition
GB202002166D0 (en) Vaccine
IL288673A (en) tgf beta vaccine
SG11202009147UA (en) Vaccine compositions
GB201910794D0 (en) Vaccine
GB201917699D0 (en) Vaccine conjugates
GB201811382D0 (en) Vaccine
EP4429699A4 (en) SARS-CoV-2 VACCINES
GB201703529D0 (en) Vaccine composition
GB202112149D0 (en) Shigellla vaccine
GB201911636D0 (en) Vaccine
GB202016954D0 (en) Vaccine
HK40063147A (en) Tgf-beta vaccine
GB202119115D0 (en) Vaccine
GB202118110D0 (en) Vaccine
GB202114274D0 (en) SARS-CoV-2 vaccine
GB202116831D0 (en) Vaccines
GB202112499D0 (en) Beta-coronavirus vaccines
GB202102677D0 (en) Vaccine
GB202109285D0 (en) Beta-coronavirus vaccines
GB202016165D0 (en) Vaccine
GB202014719D0 (en) Vaccine
GB202013534D0 (en) Vaccine
GB202013541D0 (en) Vaccine

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)